8-K: XWELL Inc. to Restate Q3 2023 Financials Due to Accounting Error, Expects Material Weakness in Internal Controls

XWELL Inc. will restate its Q3 2023 financial statements due to an accounting error related to the impairment of its Treat business segment, leading to a material weakness in internal controls.

Summary

• XWELL Inc. has identified an error in the application of U.S. Generally Accepted Accounting Principles (GAAP) related to the impairment of its Treat business segment for the three and nine months ended September 30, 2023.
• The company preliminarily estimates an understatement of impairment expenses by $1,613,000 for Q3 2023, though this figure is subject to change.
• This error necessitates a restatement of the Q3 2023 financial statements, which means the previously issued financial statements for that period should no longer be relied upon.
• The restated financials will be included in the company's Annual Report on Form 10-K for the year ended December 31, 2023.
• XWELL expects to report at least one material weakness in its internal control over financial reporting as a result of this error.
• The company's management and Audit Committee have discussed these issues with their independent registered public accounting firm, Marcum LLP.

Sentiment

Score: 3

Explanation: The document reveals a significant accounting error and a material weakness in internal controls, which are negative indicators for investors. The need for a restatement and the potential for further adjustments contribute to a low sentiment score.

Positives

• The company has identified and is addressing the accounting error.
• The error does not affect the company's previously reported cash and cash equivalents or marketable securities balances or cash runway.
• The company is working to complete the filing of its 2023 Annual Report as soon as practicable.

Negatives

• The company incorrectly applied GAAP in determining the impairment of the Treat business segment.
• The misapplication of GAAP resulted in an understatement of impairment expenses.
• The company will need to restate its Q3 2023 financial statements.
• The company expects to report at least one material weakness in its internal control over financial reporting.
• The company's internal control over financial reporting and disclosure controls and procedures were not effective for Q3 2023.

Risks

• The final impact of the misapplication of GAAP could differ from the preliminary estimate of $1,613,000.
• The company may discover additional and unanticipated information during the procedures required to complete the Annual Report.
• The application of accounting or tax principles could occur in an unanticipated manner.
• The material weakness in internal control over financial reporting could lead to future financial reporting issues.
• The restatement could negatively impact investor confidence.

Future Outlook

The company is working to complete the filing of its 2023 Annual Report, which will include the restated Q3 2023 financials. Management is assessing the effect of the restatement on the company's internal control over financial reporting and its disclosure controls and procedures.

Management Comments

• Management is assessing the effect of the Restatement on the Company's internal control over financial reporting and its disclosure controls and procedures.
• The Company expects to report at least one material weakness following completion of its analysis of the cause of the Restatement.

Industry Context

This announcement highlights the importance of accurate financial reporting and the potential consequences of accounting errors. It also underscores the need for robust internal controls to prevent such issues. This type of restatement can be damaging to investor confidence and is closely watched by regulators.

Comparison to Industry Standards

• Restatements due to accounting errors are not uncommon, but they are generally viewed negatively by investors.
• Companies in the same sector, such as travel and wellness services, are expected to maintain high standards of financial reporting.
• Comparable companies such as SpaFinder Wellness and Massage Envy are expected to have robust internal controls to prevent such errors.
• The materiality of the error, at $1.613 million, is significant enough to warrant a restatement and raises concerns about the effectiveness of XWELL's internal controls.

Stakeholder Impact

• Shareholders will be impacted by the restatement and the material weakness in internal controls.
• Employees may be affected by the changes in internal control procedures.
• Creditors may be concerned about the company's financial reporting practices.
• Customers and suppliers may experience uncertainty due to the financial restatement.

Next Steps

• The company will complete the filing of its 2023 Annual Report, including the restated Q3 2023 financials.
• Management will assess the effect of the restatement on the company's internal control over financial reporting and its disclosure controls and procedures.
• The company will report at least one material weakness following completion of its analysis of the cause of the restatement.

Key Dates

Keywords

financial restatement, accounting error, impairment, material weakness, internal controls, GAAP, Treat business segment, Q3 2023, XWELL Inc.